PDCD1 and gastroesophageal junction adenocarcinoma: demonstrated that PD-L1 CPS ≥5 is significantly associated with improved response and extended PFS in advanced gastric or gastroesophageal junction adenocarcinoma patients treated with a combination of PD-1 inhibitors and chemotherapy (25).